title: Postoperative adjuvant radiotherapy and 5-fluorouracil chemotherapy for rectal carcinoma.
abstract: Postoperative combined modality therapy with radiotherapy and 5-fluorouracil (5FU) chemotherapy is an effective adjuvant approach that reduces locoregional and distant metastatic disease in patients with high-risk rectal carcinoma. However, this approach results in a treatment regimen of at least 6 months' duration. The present prospective study investigates the integration of radiotherapy and 5FU chemotherapy in a protocol designed to minimize toxicity and reduce the overall treatment time. A total of 40 patients with TNM stage II or III disease received postoperative radiotherapy at four fractions per week with weekly 5FU bolus injections delivered on the fifth non-radiotherapy day. Patients also received systemic chemotherapy with leucovorin both before and after pelvic irradiation, with the total treatment duration extending for only 18 weeks. Patients were able to complete radiotherapy in 90% of cases, while the delivery of full-dose chemotherapy was achievable in the vast majority. The incidence of haematologic and gastrointestinal toxicities requiring the cessation of treatment was acceptable. With a median follow-up of 20.9 months among surviving patients, the estimated progression-free and overall survival at 2 years were 71% and 79%, respectively.
authors.affiliation: Division of Radiation Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.
authors.forename: M W
authors.initials: MW
authors.lastname: Chao
authors.forename: D
authors.initials: D
authors.lastname: Byram
authors.forename: R
authors.initials: R
authors.lastname: Bell
authors.forename: R
authors.initials: R
authors.lastname: Bond
authors.forename: S
authors.initials: S
authors.lastname: Vaughan
authors.forename: R
authors.initials: R
authors.lastname: McLennan
authors.forename: M
authors.initials: M
authors.lastname: Lim-Joon
authors.forename: M
authors.initials: M
authors.lastname: Wada
authors.forename: D
authors.initials: D
authors.lastname: Joseph
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000628:therapy*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D018714:Radiotherapy, Adjuvant; D011882:Radiotherapy, High-Energy; D012004:Rectal Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
chemical_list: D000964:Antimetabolites, Antineoplastic; D002955:Leucovorin; D005472:Fluorouracil